Skip to content

Prevalence and Severity of Treatment-Related Symptoms in Hepatocellular Carcinoma: A Prospective Analysis of HAIC Combined with Targeted and Immunotherapeutic Agents

Prevalence and Severity of Treatment-Related Symptoms in Hepatocellular Carcinoma: A Prospective Analysis of HAIC Combined with Targeted and Immunotherapeutic Agents

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126797
Enrollment
Unknown
Registered
2026-06-16
Start date
2026-06-30
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Hepatic Arterial Infusion Chemotherapy (HAIC) with targeted therapy and immunotherapy:None

Sponsors

Sun Yat-sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years, both males and females are eligible; 2.Undergoing HAIC combined with targeted therapy and immunotherapy; 3. Meeting the diagnostic criteria for hepatocellular carcinoma (HCC) with confirmed diagnosis; 4.Within 72 hours postoperatively; 5.Mentally clear and without other major comorbidities; 6.Having signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients who have been diagnosed with mood disorders during the treatment period and are currently taking medication or receiving therapy; 2.Postoperative period exceeding 72 hours; 3.Patients lacking independent cognitive/decision-making capacity; 4.Patients who have not signed the informed consent form and refuse to complete questionnaires.

Design outcomes

Primary

MeasureTime frame
Functional assessment of anorexia/cachexia treatment (faact a/cs);Visual analogue scale (VAS) score of appetite;Pittsburgh sleep index (posi) score;Hospital Anxiety and Depression Scale (HADS) Score;EORTC Quality of Life Questionnaire QLQ-C30 (Version 3.0) Results;Chinese Version of the Memorial Symptom Assessment Scale (MSAS-Ch);

Countries

China

Contacts

Public ContactYanxia Huang

Sun Yat-sen University Cancer Center

huangyx1@sysucc.org.cn+86 20 87341841

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 29, 2026